SCHEMBL2095656

SCHEMBL2095656

CCCCOc1ccc(NC(=O)OC)cc1

nearest known ligand 0.68

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FAAH O00519 18/20 0.68
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2091833 0.97 FAAH (0.70) FAAH
SCHEMBL2095422 0.95 FAAH (0.72) FAAH
SCHEMBL2096010 0.95 FAAH (0.72) FAAH
SCHEMBL2095676 0.95 FAAH (0.72) FAAH
SCHEMBL11662947 0.93 FAAH (0.68) FAAHNPC1RAB9ASMN1; SMN2
SCHEMBL2095653 0.87 FAAH (0.65) FAAH
SCHEMBL2091634 0.86 CYP1A2 (0.71) FAAHNPC1RAB9ASMN1; SMN2
SCHEMBL10338248 0.85 ALDH1A1 (0.73) FAAHNPC1RAB9ASMN1; SMN2
SCHEMBL3223930 0.84 LMNA (0.74) FAAHSMN1; SMN2
SCHEMBL5218010 0.84 GAA (0.64) FAAHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507453-B2 Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2013-08-13 US disclosed
US-8507453-B2 Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2013-08-13 US disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20120015896-A1 Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION 2012-01-19 US disclosed
US-20120015896-A1 Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION 2012-01-19 US disclosed
US-8053418-B2 Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2011-11-08 US disclosed
US-8053418-B2 Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2011-11-08 US disclosed
US-20080300388-A1 Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2008-12-04 US disclosed
US-20080300388-A1 Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2008-12-04 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-20070185135-A1 Drug-Polymer Conjugates PHARMAESSENTIA CORP. 2007-08-09 US disclosed
US-4487713-A HEAT TREATMENT WITH TITANIUM, TIN, ANTIMONY OR ZIRCONIUM COMPOUND EXXON RESEARCH & ENGINEERING CO. (US) 1984-12-11 US disclosed
US-4081472-A CATALYTIC, FROM A CARBAMATE MITSUI TOATSU CHEMICALS INC. (JA) 1978-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015896-A1 Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative PWWP2B, BRWD1, BAZ1A FAAH 4658/4885NPC1 2009/4885RAB9A 113/4885
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 FAAH 3448/4885NPC1 3130/4885RAB9A 3153/4885
US-20070185135-A1 Drug-Polymer Conjugates LNPEP, MSN, ANPEP FAAH 1627/4885NPC1 1708/4885RAB9A 4234/4885
US-20080300388-A1 Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative PWWP2B, BRWD1, BAZ1A FAAH 4658/4885NPC1 2009/4885RAB9A 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.